Reduced ferroxidase activity in the cerebrospinal fluid from patients with Parkinson's disease

Neuroscience Letters

Volumn 265, Issue 3, 1999, Pages 155-158

  Boll, Marie Catherine ^a   Sotelo, Julio ^a   Otero, Enrique ^a   Alcaraz Zubeldia, Mireya ^a   Rios, Camilo ^a  

^a NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

Author keywords

Cerebrospinal fluid; Ceruloplasmin; Copper; Ferroxidase activity; Iron; Parkinson's disease

Indexed keywords

CERULOPLASMIN; COPPER; IRON; LEVODOPA;

ADULT; ARTICLE; BASAL GANGLION; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; COPPER METABOLISM; DISEASE COURSE; ENZYME ACTIVITY; FEMALE; HUMAN; IRON STORAGE; MALE; NERVE CELL NECROSIS; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

AGED; ANTIPARKINSON AGENTS; CERULOPLASMIN; COPPER; ENZYME ACTIVATION; FEMALE; HUMANS; IRON; LEVODOPA; MALE; MIDDLE AGED; OXIDATIVE STRESS; PARKINSON DISEASE;

EID: 0033597299     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(99)00221-9     Document Type: Article

References (20)

1. Arnaud Ph., Gianazza E., Miribel L. Study of acute-phase reactants. Methods Enzymol. 163:1988;441-448.
2. Bonnet J.J., Benmansour S., Amejdki-Chab N., Costentin J. Effect of CH3-HgCl and several transition metals on the dopamine neuronal carrier. Eur. J. Pharmacol. 266:1994;87-97.
3. Crowe A., Morgan E.H. Iron and copper interact during their uptake and deposition in the brain and other organs of developing rats exposed to dietary excess of the two metals. J. Nutr. 126:1996;183-194.
4. Dexter D.T., Carayon A., Javoy-Agid F., Agid Y., Wells F.R., Daniel S.E., Lees A.J., Jenner P., Marsden C.D. Alterations in the levels of iron, ferritin, and other trace metals in Parkinson' s disease and other neurodegenerative diseases affecting the basal ganglia. Brain. 114:1991;1953-1975.
5. Fahn, S. and members of the UPDRS Development Committee, Unified Parkinson's Disease Rating Scale. Recent Developments in Parkinson's Disease, Vol. II, McMillan, NJ, 1987, pp. 153-163.
6. Gerlach M., Ben Shachar D., Riederer P., Youdim B.H. Altered brain metabolism of iron as a cause of neurodegenerative diseases. J. Neurochem. 63:1994;793-807.
7. Harris Z.L., Takahashi Y., Miyajima H., Serizawa M., McGillivray R.T.A., Gitlin J.D. Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. Proc. Natl. Acad. Sci. USA. 92:1995;2539-2543.
8. Hartmann H.A., Everson M.A. Deficiency of copper can cause neuronal degeneration. Med. Hypoth. 38:1992;75-85.
9. Hoehn M.M., Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology. 17:1967;422-427.
10. Jenner P., Schapira A.H., Marsden D. New insights into the cause of Parkinson's disease. Neurology. 42:1992;2241-2250.
11. Loeffler D.A., LeWitt P.A., Jumeau P.L., Sima A.A.F., Nguyen H.U., DeMaggio A.J., Brickman C.M., Brewer G.J., Dick R.D., Troyer M.D., Kanaley L. Increased regional brain concentrations of ceruloplasmin in neurodegeneratives disorders. Brain Res. 738:1996;265-274.
12. Miyajima H., Takahashi Y., Serizawa M., Kaneko E., Gitlin J.D. Increased plasma lipid peroxidation in patients with aceruloplasminemia. Free Rad. Biol. Med. 20:1996;757-760.
13. Morita H., Ikeda S., Yamamoto K., Morita S., Yoshida K., Nomoto S., Kato M., Yanagisawa N. Hereditary ceruloplasmin deficiency with hemosiderosis: a clinicopathological study of a Japanese family. Ann. Neurol. 37:1995;646-656.
14. Olanow C.W., Drayer B. Magnetic resonance imaging studies of iron distribution in Parkinson's disease and aging. Arch. Neurol. 45:1988;809.
15. Pall H.S., Blake D.R., Gutteridge J.R., Williams A.C., Lunec J., Tailor A. Raised cerebrospinal-fluid copper concentration in Parkinson's disease. Lancet. 2:1987;238-241.
16. Patel B.N., Davis S. A novel glycosylphosphatidylinositol-anchored form of ceruloplasmin is expressed by mammalian astrocytes. J. Biol. Chem. 272:1997;20185-20190.
17. Rios C., Alvarez-Vega R., Rojas P. Depletion of copper and manganese in brain after MPTP treatment of mice. Pharmacol. Toxicol. 76:1995;348-352.
18. Rojas P., Rios C. Increased striatal lipid peroxidation after intracerebro ventricular MPP+ administration to mice. Pharmacol. Toxicol. 72:1993;364-368.
19. 2+) complex: a possible mechanism of nigrostriatal cell damage. Arch. Biochem. Biophys. 283:1990;334-341.
20. Tanabe S., Shiori T., Murakami K., Imanari T. A new method for assay of ferroxidase activity and its application to human and rabbit sera. Chem. Pharm. Bull. 32:1984;4029-4035.